Trial · NCT01059643
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Colorectal Cancer | 0 | 90% Confidence Interval 0.0 to 17.1 | percentage of participants |
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Gastroesophageal Cancer | 0 | 90% Confidence Interval 0.0 to 22.1 | percentage of participants |
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Non-Small Cell Lung Cancer | 0 | 90% Confidence Interval 0.0 to 10.9 | percentage of participants |
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Ovarian Cancer | 0 | 90% Confidence Interval 0.0 to 20.6 | percentage of participants |
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Prostate Cancer | 0 | 90% Confidence Interval 0.0 to 16.2 | percentage of participants |
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | LY2523355 | Squamous Cell Carcinoma of Head and Neck | 0 | 90% Confidence Interval 0.0 to 25.9 | percentage of participants |
| Progression Free Survival (PFS) | LY2523355 | Colorectal Cancer | 1.30 | 90% Confidence Interval 1.28 to 2.69 | months |
| Progression Free Survival (PFS) | LY2523355 | Gastroesophageal Cancer | 1.25 | 90% Confidence Interval 0.62 to 1.51 | months |
| Progression Free Survival (PFS) | LY2523355 | Non-Small Cell Lung Cancer | 1.31 | 90% Confidence Interval 1.28 to 1.91 | months |
| Progression Free Survival (PFS) | LY2523355 | Ovarian Cancer | 1.31 | 90% Confidence Interval 1.18 to 2.10 | months |
| Progression Free Survival (PFS) | LY2523355 | Prostate Cancer | 2.30 | 90% Confidence Interval 1.45 to 2.66 | months |
| Progression Free Survival (PFS) | LY2523355 | Squamous Cell Carcinoma of Head and Neck | 1.51 | 90% Confidence Interval 0.72 to 2.76 | months |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Colorectal Cancer | 37.5 | 90% Confidence Interval 17.8 to 60.9 | percentage of participants |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Gastroesophageal Cancer | 16.7 | 90% Confidence Interval 3.0 to 43.8 | percentage of participants |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Non-Small Cell Lung Cancer | 38.5 | 90% Confidence Interval 22.6 to 56.4 | percentage of participants |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Ovarian Cancer | 30.8 | 90% Confidence Interval 11.3 to 57.3 | percentage of participants |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Prostate Cancer | 47.1 | 90% Confidence Interval 26.0 to 68.9 | percentage of participants |
| Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | LY2523355 | Squamous Cell Carcinoma of Head and Neck | 50.0 | 90% Confidence Interval 22.2 to 77.8 | percentage of participants |
| Tumor Marker Values as Relevant to Specific Tumor Types at Baseline | LY2523355 | CRC-BRAF Mutation, Negative | 2 | Participants | |
| Tumor Marker Values as Relevant to Specific Tumor Types at Baseline | LY2523355 | CRC-BRAF Mutation, Not Done/Unknown | 15 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01059643/results